AAV2 vector system (AAV2 expression system, AAV2 packaging plasmid system) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi (GM) AAV2 Vector system is including: 1) AAV2 Rep-Cap plasmid (AAV2-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).

You can produce AAV2 particle in 293T cell line in high titer using GeneMedi's AAV2 Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV2 vector has been validated in retina, liver and kidney, with potential applications in tissue-specific gene therapy.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.

Target products collectionGo to AAV vector system >>

pdfManual pdfProtocol pdfMap Download

Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-PK02 AAV2 Vector System (Amp resistance)
1. AAV2 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Academic 2028
P-PK02 AAV2 Vector System (Amp resistance)
1. AAV2 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-PK02 AAV2 Vector System (Amp resistance)
1. AAV2 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK02 AAV2 Vector System (Amp resistance)
1. AAV2 Rep-Cap Plasmid, ≥10mg
2. AAV Helper Plasmid, ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg
 All
P-PK02-Kan AAV2 Vector System (Kan resistance)
1. AAV2 Rep-Cap Plasmid (Kan resistance) , ≥10mg
2. AAV Helper Plasmid (Kan resistance) , ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg
 All
P-RC02 AAV2 Rep-Cap Plasmid (Amp resistance)
Size：5ug 		Academic 935
P-RC02 AAV2 Rep-Cap Plasmid (Amp resistance)
Size：5ug 		Industry R&D
(excluding
CRO&CDMO&CXO)
P-RC02 AAV2 Rep-Cap Plasmid (Amp resistance)
Size：5ug 		CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC02 AAV2 Rep-Cap Plasmid (Amp resistance)
Size：≥10mg 		All
P-RC02-Kan AAV2 Rep-Cap Plasmid(Kan resistance)
Size：≥10mg 		All
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System.
GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production& amplification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
Metabolic regulation of homologous recombination repair by MRE11 lactylation Cell 2023/12/18
Moderate UV Exposure Enhances Learning and Memory by Promoting a Novel Glutamate Biosynthetic Pathway in the Brain CELL 2018/6/14
Rhythmic Cilia Changes Support SCN Neuron Coherence in Circadian Clock Science 2023/6/2
Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression Science 2022/8/4
METTL3-mediated N6-methyladenosine mRNA modification enhances long-term memory consolidation Cell Research 2018/10/8
An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia–reperfusion injury NATURE MEDICINE 2017/12/11
Hepatic glucuronyl C5-epimerase combats obesity by stabilising GDF15 Journal of Hepatology 2023/5/20
Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice Journal of Hepatology 2022/11/8
3’untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein European Heart Journal 2021/5/15
Neuraminidase 1 is a driver of experimental cardiac hypertrophy European Heart Journal 2021/6/28


Validation data

transduction results of AAV2 (left) /AAV-DJ (middle) / AAV9 (right) in tumor
Figure. Selected transduction results of AAV2 (left) /AAV-DJ (middle) / AAV9 (right) in tumor.

Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml
Animal: Nude mouse, 2 months
Infection site: Subcutaneous transplant of bowel cancer cells
Gene delivery method: Tumor injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

transduction of AAV2 variant (Y444F) vector system in mouse retina
Figure. Selected transduction results of AAV2 variant(Y444F) vector system in mouse retina.

Virus and titer: AAV2 variant(Y444F) vector system, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy

transduction of AAV2 variant (AAV2.7m8) vector system in mouse retina
Figure. Selected transduction results of AAV2 variant (AAV2.7m8) vector system in mouse retina.

Virus and titer: AAV2 variant (AAV2.7m8) vector system, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail